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Background: Osteoarthritis (OA) in the horse is an economic and welfare issue and
there are no current diseasemodifying drugs available. Stem cells have been suggested as
a therapeutic intervention for OA, originally on the basis of their regenerative capacity.
However, it is hypothesised that mesenchymal stem cells (MSC) exert their effects via
paracrine factors including the production of extracellular vesicles that can themselves
recapitulate the MSC effects in the joint.
Objectives:To isolate extracellular vesicles frombonemarrowMSCand investigate their
anti-inflammatory effects on chondrocytes.
Study design: An in vitro assessment of the effect of direct culturing extracellular vesi-
cles on artificially inflamed chondrocytes.
Methods: Extracellular vesicles were isolated from bonemarrowMSC using differential
sequential ultracentrifugation. Vesicles were characterised using electron microscopy,
nanoparticle tracing analysis and protein analysis. Vesicle internalisationwas carried out
via vesicles being pre-stained and co-cultured with equine chondrocytes before analysis
using confocal microscopy. The effects of vesicles on artificially inflamed chondrocytes
was examined using quantitative PCR.
Results:To the best of the authors’ knowledge, this is the first study to isolate and charac-
terise extracellular vesicles from equine boneMSC.Vesicles were taken up by autologous
chondrocytes and had anti-inflammatory effects on gene expression following chondro-
cyte exposure to tumour necrosis factor α and Interleukin 1β.
Main limitations: Only three independent biological repeats were performed and the
work was done in vitro.
Conclusion: Extracellular vesicles can be isolated from equine bone marrowMSC; they
may be taken up by chondrocytes and have an anti-inflammatory action.
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INTRODUCTION
The use ofmesenchymal stem/stromal/signalling cells (MSC)1
to treat orthopaedic diseases in horses has becomewidespread
in the last decade2,3 with tendon/and ligament injuries, syn-
ovitis, osteoarthritis (OA) and cartilage lesions all being
considered as candidates for MSC therapy. Whilst the
majority of MSC therapies have been performed using
autologous cells, the increasing commercialisation of stem
cell therapies has led to the launch of allogeneic MSC
products.4
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In the horse OA is a major cause of lameness and poor
performance. Characterised by changes in the joint includ-
ing synovitis and subchondral bone abnormalities, it leads
to degeneration of articular cartilage.5 Treatment of OA is
challenging, with no disease modifying therapies available.
Non-steroidal anti-inflammatory drugs are commonly given
to alleviate signs such as pain and inflammation; however, they
do not restore the cartilage to its previous condition. The use
of MSC to treat equine OA has increased in recent years and
whilst intra-articularMSC are considered to be safe to admin-
ister, it is well recognised that, in the horse, these injections can
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cause transient inflammation and synovitis.6 There are several
different sources of bone marrow MSC in the body including
from various limbs; however, the anatomical location of
these tissues does not affect the function of the cells.7,8 Addi-
tionally, there are other complications and disadvantages of
using MSC including limited cell survival, immune-rejection,
senescence-induced genetic instability or loss of function and
the theoretical risk of malignant transformation.9,10
The original theories to explain the beneficial effects of
MSC proposed that their mechanism of action was primar-
ily to engraft and regenerate damaged tissue. However, it has
become clear that this ‘engraftment and build’ concept is not
supported by evidence. It has now been demonstrated that
MSC exert their effect via paracrine actions through the secre-
tion of anti-inflammatory and regenerative factors;11,12 that
many of these paracrine actions have been demonstrated to
reside in small, membrane bound particles, extracellular vesi-
cles (EV), secreted by the MSC.13
Extracellular vesicles are secreted by all cells and are
involved in cell–cell communication;14 they are sub-classified
depending on their size into exosomes (40–100 nm),
microvesicles (100–1,000 nm) and apoptotic bodies (100–
5,000 nm).15 They act as a paracrine signalling system,
stably transporting proteins, RNAs [rRNA, tRNA, miRNA,
lnc(RNA)] and mitochondrial DNA through the extracellular
environment.16,17 Extracellular vesicles attach to the recipient
cell membrane and are internalised, exerting their effects by
direct ligand–receptor interactions on the cell surface or by
intracellular effects of their cargo including affecting gene
expression through de novo translation and post-translation
regulation of target mRNAs.18 Thus, EV can theoretically
recapitulate the therapeutic effects of their parent cell. 16,19
The characterisation of human EV has been extensively
reported.11 The identification of human cells based on their
protein characterisation is considered good practice. In
commonly used non-human MSC sources, such as mouse
and rat, such protein characterisation has not routinely been
performed.20
In vivo, bone marrow derived mouse MSC EV have been
reported to prevent cartilage breakdown21 in the joint and, as
cell-free,minimally immunogenic particles, EVmay represent
an opportunity for equine joint disease treatment and regener-
ation. The aims of this study were i) to isolate and characterise
EV from horse bone marrow derivedMSC (BM-MSC) and ii)
to investigate the effect of these EV on chondrocytes cultured
in a pro-inflammatory environment in vitro.
METHODS
Animals
Bone marrow and cartilage was collected postmortem from
three adult horses (aged 18-24 years) (one male, two female)
that were euthanased for reasons other than orthopaedic dis-
ease with no inflammatory related diseases at the Depart-
ment of Veterinary Medicine, University of Cambridge, UK
with full ethical consent from the owners. The femoro-patellar
joints were dissected and a visual inspection of the cartilage
surface carried out to ensure no cartilage abnormalities were
detected.
Cell harvest and culture
Bone marrow was aspirated from the medullary cavity of
the distal femur and collected into 2,000 U/ml sterile Hep-
arin (Sigma, UK) diluted in phosphate buffered saline (PBS)
(Sigma, UK) at 4◦C. Between 5 and 10 ml of bone mar-
row was collected from each donor. The marrow was passed
through a 70 μm cell strainer (Miltenyi, UK), before under-
going two rounds of centrifugation (300 × g, 5 min at room
temperature). The supernatant was discarded and the pel-
let re-suspended in standard culture media. Standard cul-
ture media consisted of α-MEM (Invitrogen, UK), supple-
mented with 10% fetal calf serum (FCS) (First Link, UK),
1% penicillin/streptomycin (Sigma, UK), 1% Glutamax (Ther-
mofisher, USA), 5 μg/ml ascorbic acid (Sigma, UK) and
50 ng/ml Human Fibroblast Growth Factor Beta (Peprotech,
USA). Cells were initially plated in T75 flasks and after a first
passage they were then cultured in T175 flasks (Fisher, UK).
Cartilage was removed from the articular surface of the dis-
tal femur using sharp dissection and collected into α-MEM at
4◦C. Cartilage fragments were washed in PBS, before being
dissected into <1 mm3 pieces. The cartilage was then incu-
bated in 0.2% collagenase II (Roche, Germany) dissolved in
standard culture media overnight under standard tissue cul-
ture conditions (humidified incubator (Sanyo, UK) at 37˚C
and 5% CO2). The contents of the flask were then filtered
(70 μm nylon cell strainer). Of the filtered substrate, any cells
were pelleted from solution via centrifugation (300 × g, 5
min). The pellet was re-suspended and plated for cell culture
in standard tissue culture medium and under standard tissue
culture conditions. Cells were cultured in T175 flasks.
All cells were cultured in a humidified incubator (Sanyo,
UK) at 37˚C and 5% CO2. Upon reaching 80% confluence,
cells were passaged using trypLE (Life Technologies, USA).
In brief, culture media was removed and 100 μl/cm2 trypLE
was added to the culture flask. The cells were incubated with
trypLE for 10 min before mild agitation to detach the cells.
The cell containing trypLEwas then collected and centrifuged
at 300 × g for 5 min. The supernatant was discarded, the cells
re-suspended in PBS; an aliquot was counted with a haemocy-
tometer before the cells were re-centrifuged and re-suspended
in an appropriate volume of culturemedia and the cells plated.
Tri-lineage differentiation of MSCs
Upon reaching approximately 80% confluence at passage 2,
the cells were passaged as above before being cultured in the
appropriate differentiation medium.
Chondrogenic differentiation
A total of 2 × 105 MSC were centrifuged at 300 × g for 5 min
to form a pellet and were then cultured in Stempro Chon-
drogenic differentiation media (Life technologies, UK) for
21 days under standard cell culture conditions with media
changes every 3–4 days in a 15 ml polypropylene falcon tube
(Greiner Bio-one, Australia). The pellet was then fixed in 4%
paraformaldehyde (Sigma, UK) for 1 h before paraffin embed-
ding, sectioning at 5μm, stainingwithAlcian Blue and imaged
using light microscopy.
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F IGURE  A schematic to demonstrate differential sequential ultracentrifugation for EV isolation from equine bone marrow-derived MSC.
Conditioned media was centrifuged at 300 × g for 5 min, 2,000 × g for 20 min at 4◦C, 10,000 × g for 45 min at 4◦C, 100,000 × g for 90 min at 4◦C under vacuum
Osteogenic differentiation
A total of 2× 105 MSCwere plated into a 6-well platewith stan-
dard culture media for 24 h. The media was then removed,
and the cells washed once with PBS before being cultured
in osteogenic differentiation media [culture media, 3.5 mM
β glycerophosphate (Sigma, UK), 100 nm dexamethasone
(Sigma, UK)]22,23 with media changes every 3–4 days. Cells
were cultured in differentiation media for 21 days before the
media was removed, and the cells washed once with PBS and
fixed with formalin for 1 h. After fixing, the cells were covered
with 0.5% (W/V) alizarin red (pH 4.1). The cells were stained
for 15 min before the alizarin red was removed and the cells
washed in PBS five times before being left to air dry before
analysis using light microscopy.
Adipogenic differentiation
A total of 1 × 105 MSC were cultured in 6-well plates for 24 h
in standard culture conditions before the media was removed,
and the cells washed and StemPro Adipogenesis media (Life
Technologies, UK) being added to the cells. The media was
changed every 3–4 days, and the cells were cultured for 14 days
before being fixed with formalin and stained with oil-red-o
solution (0.1% V/V) for 1 h. The stain was removed and the
cells washed with PBS before imaging and analysis under light
microscopy.
Differential sequential ultracentrifugation for
extracellular vesicle isolation
Extracellular vesicles were isolated from passage 3 BM-MSC.
At passage 3, standard culture media was removed from the
cells, which were then washed with PBS and then cultured
in FCS free media for 48 h under standard culture con-
ditions. This media was then collected and centrifuged at
300× g for 5min, before the supernatant was collected and re-
centrifuged at 2,000 × g for 20 min. The supernatant was then
ultra-centrifuged using anOptima XPN 100-K Floor Standing
Ultracentrifuge (Beckman, UK) using a SW32 swing bucket
rotor (Beckman,UK) at 10,000× g for 45min. The supernatant
was again collected and re-centrifuged at 100,000 × g for 90
min. The supernatant was then discarded and the pellet re-
suspended in PBS and ultra-centrifuged again at 100,000 × g
for 90 min at 4◦C. The pellet was re-suspended in PBS and
frozen at −70˚C. Figure 1 illustrates the process of EV isola-
tion via differential sequential ultracentrifugation.
Nanoparticle tracking analysis (NTA)
NTA analysis was performed and analysed using a NanoSight
LM10 Nanoparticle Analysis system (Malvern, UK) and NTA
3.2 analytical software as per the manufacturer’s instructions.
The EV suspension was diluted to give an average parti-
cles/frame count of 50 before analysis.
Transmission electron microscopy
An EV suspension was placed on a ‘glow discharge disk’ pre-
pared by the Cambridge Advanced Imaging Centre (CAIC).
The EV loaded disk was then negatively stained with 2%
uranyl acetate (Sigma, USA) for 2 min at room temper-
ature, before washing with PBS twice, ready for viewing
using TEM. In brief, TEM was performed with a Tecnai
G2 TEM (FEI/ThermoFisher) using an accelerating volt-
age of 200 keV and a 20 μm objective aperture to improve
contrast. Images were acquired with an ORCA HR high-
resolution CCD camera with a Hamamatsu DCAM board
running Image Capture Engine software, version 600.323
(Advanced Microscopy Technology Corp., Danvers, MA,
USA).
Bicinchoninic acid (BCA) protein assay
The protein content of the EV suspension was measured
using the Pierce BCA Protein Assay Kit as per the manufac-
turer’s instructions (Thermoscientific, UK). An aliquot of EV
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suspension was used to quantify surface protein or added to
20% sodium dodecyl sulphate for 20 min (Sigma, UK) to lyse
the EV and quantify total protein.24 The percentage surface
and internal protein was then calculated.
Internalisation
Extracellular vesicles from 4 × 104 MSCs were labelled with
the fluorescent dye PKH67 (Sigma, UK) via incubation at
room temperature for 30 min as per manufacturer’s instruc-
tions. In brief, the EV were suspended in 994 μl of Diluent
C (Sigma, UK) and 6 μl of PKH67. The reaction was then
quenched via the addition of 10% Bovine Serum Albumin
(BSA) (Sigma, UK). The EV were pelleted via centrifugation
at 100,000 × g for 90 min and the supernatant containing
unbounddyewas removed. The pellet was thenwashed via the
addition of 1ml of 10%BSA and re-centrifuged to ensure com-
plete quenching and removal of any unbound dye. The super-
natant was removed and the pellet was then re-suspended in
PBS and washed once more via this centrifugation process
before culture with equine chondrocytes for 1 h under stan-
dard culture conditions. After 1 h, cells were fixed with for-
malin for 1 h before the cell membranes were stained with
WGA-55 (Thermofisher, UK) as per manufacturer’s instruc-
tions. Cells were permeabilised by the addition of 10% Triton
X and 10% BSA in PBS for 20min before nuclear staining with
DAPI. Cells were imaged via confocalmicroscopy (Leica SP5).
Effect of extracellular vesicles on chondrocytes
grown under inflammatory conditions
A total of 2.5 × 105 equine chondrocytes were cultured in the
presence of either Interleukin-1β (IL-1β) or tumour necrosis
factor-α (TNF-α) at concentrations of 1 and 2 ng/ml. After 12 h
of culture, EV that had been isolated from 2.5 × 105 MSC by
differential sequential ultracentrifugation and re-suspended
in 5–10 μl of room temperature PBS were added to the stan-
dard culture medium, equivalent to a 1:1 ratio of chondro-
cytes:MSC.
After 72 h of culture in the presence of EV, culture media
was removed from the cells and 300 μl of RNA lysis buffer
(QUIazol, Qiagen, Germany) was added. mRNA extraction
was performed using the Direct-zol mRNA microprep kit as
per manufacturer’s instructions (Zymo, USA). cDNA synthe-
sis was then performed using aQuantiTect Reverse Transcrip-
tion Kit (Qiagen, Germany). MMP-13, ADAMTS4, ACAN
and HPRT primers were obtained. Primers sequences (5′ to
3′) are shown in Table 1.
The qPCR analysis was performed using a QuantiFast
SYBR Green PCR Kit (Qiagen, Germany) in a StepOnePlus
Machine (ThermoFisher, UK). Target genes were nor-
malised using the housekeeping gene hypoxanthine-guanine
phosphoribosyltransferase (HPRT-1) and the relative gene
expression was calculated by comparing 2−ΔCt values.
Statistics
All statistical work was performed using a one-way
ANOVA with a Tukey’s multiple comparisons test using
GraphPad Prism 9, version 9.0.0 (121). If *p < 0.05,
**p < 0.01,***p < 0.001.
RESULTS
Bone-marrow-derived mesenchymal stem cell
differentiation
Cells obtained from bone marrow were demonstrated to be
adherent to tissue culture plastic and capable of tri-lineage
differentiation into adipocytes (Figure 2a), chondrocytes
(Figure 2b) and osteoblasts (Figure 2c) in the appropriate
culture media.
Extracellular vesicles production, isolation
and characterisation
Extracellular vesicles were obtained from BM-MSC from
three horses via differential sequential ultracentrifuga-
tion, with the mean yield of EV 4.61 × 1010/million MSCs
(±0.89 × 1010 = 2 × SD). The EV obtained were characterised
in several ways. First, transmission electron microscopy
(TEM) was used to directly visualise the EV. TEM confirmed
that the particles isolated by differential sequential ultracen-
trifugation were circular structures with a heterogeneous size,
characteristic of EV (Figure 3a). The size of the EV produced
by differential ultracentrifugation was measured with NTA.
This showed that the mean size of the EV isolated was 186 nm
[±3.9 nm (SD)] (Figure 3b), with the size of the EV at the
smallest 10th percentile to be 128.3 nm (±4.7 nm) at the 50th
percentile 168.9 nm (±4.8 nm) and at the 90th percentile to
be 259 nm (±4.8 nm) (Figure 3c). Total protein analysis using
a BCA revealed that 86.5% (±6.6%) of the total EV protein
content was on the surface of the EV (Figure 3d).
Extracellular vesicle internalisation
In order to demonstrate that EV were taken up by chondro-
cytes, confocal microscopy was performed. Autologous chon-
drocytes were cultured in monolayer and then co-cultured
with or without pre-labelled EV (Figure 4). Extracellular vesi-
cles were detected within the chondrocytes (Figure 4), con-
firming that the chondrocytes were able to internalise the EV.
The EV were located in the cytoplasm of the chondrocytes.
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F IGURE  Tri-lineage differentiation of bone marrow-derived MSC (BM-MSC).
The BM-MSC were cultured in adipogenic, chondrogenic and osteogenic media for up to 21 days. (a) Staining with Oil-Red-O showing the presence of red fat
vacuoles stained red confirming adipogenesis (phase contrast imaging). (b) Staining with Alcian blue showing the presence of blue chondrocytes confirming
chondrogenesis (bright field microscopy). (c) Staining with alizarin red showing the presence of red mineral staining confirming osteogenesis (phase contrast
microscopy) (n = 3) (scale bar = 100 μm)
F IGURE  Extracellular vesicles (EV) characterisation
(a) Transmission electron microscopy showing isolated EVS have a circular morphology and that different EVs have different sizes. Scale bar = 100 nm. (b)
Nanoparticle tracking analysis showing the size distribution of the EV population was 45–450 nm characteristic of EV. The size of the EV at the 10th, 50th and
90th percentile is also shows the variation in sizes across the sample population. (c) The mean particle size was 182.48 nm with a heterogeneity of sizes across
the sample. (d) Analysis of protein content of the EVs showed that the mean percentage of EV surface protein in comparison to the internal protein is 86%
(±7% 1 × SD). Error bars = 1 × SD (n = 3)
The effect of bone marrow-derived MSC
extracellular vesicles on chondrocytes cultured
under inflammatory conditions
Chondrocytes were cultured under inflammatory conditions
and RT-qPCR performed to assess the effects of culture
on gene expression of MMP13 (Figure 5a), ADAMTS4
(Figure 5b) and ACAN (Figure 5c) in the presence of autol-
ogous EV-derived from BM-MSC. Gene expression was
calculated relative to the housekeeping gene HRPT.
In chondrocytes treated with both 1 and 2 ng/ml IL-1β a
dose dependant increase in MMP13 was observed, when cul-
tured in the presence of EVMMP13 levels decreased. This was
significant at a IL-1β concentration of 2 ng/ml. A similar effect
was detected when chondrocytes were treated with TNFα,
that is, MMP13 levels increased with increasing cytokine
concentrations and the presence of EV decreased the
expression of MMP13, although a significant decrease in
MMP13 expression in the presence of EV was only observed
at a concentration of 2 ng/ml of TNFα.
 of  Veterinary Record Open
F IGURE  Confocal imaging of equine chondrocytes showing internalisation of bone marrow derived mesenchymal stem cell extracellular vesicles
(MSC-EV).
Three images from the confocal z-stack (top, middle and bottom, respectively) showing EVs pre-stained with PKH67 (green) and internalised by an equine
chondrocyte stained with the membrane stain WGA-555 (red) and nuclei stain (blue). This figure shows the EV primarily located in the middle of the cell.
Scale bar = 50 μm (n = 3)
F IGURE  The effect of extracellular vesicles on chondrocyte MMP-, ADAMTS and ACAN gene expression.
Gene expression in chondrocytes cultured in the presence of IL-1β and TNF-α at concentrations of 1 or 2 ng/ml in the presence and absence of autologous bone
marrow MSC-derived EV. MMP-13 gene expression is increased in the presence of IL-1β and TNF-α in a dose dependant manner. This increase in MMP13
expression is abrogated when EV are applied to the chondrocytes but is only significant at concentrations of 2 ng/ml (p < 0.05) (a). Similarly, ADAMTS4 gene
expression is increased in the presence of IL-1β and TNF-α and as the concentration of both cytokines increases, so does the ADAMTS4 expression. However,
upon exposure to autologous BM-MSC EV, the increase in ADAMTS4 gene expression was lost (b) (p < 0.05). Upon exposure to 1 ng/ml of IL-1β, chondrocyte
ACAN gene expression remained higher than any of the other cytokine treatment variables (2 ng/ml IL-1β, 1/2 ng/ml TNF-α). Upon exposure to EV and IL-1β
at either concentration, there was no significant difference in ACAN gene expression (c). Upon exposure to TNFα, there was no significant difference in ACAN
exposure and a non-significant increase was observed when EVwere applied. Error bars= 1× SD, ***p< 0.005, **p< 0.01, *p< 0.05. NS= not significant (n= 3)
Similar effects were seen with regards to ADAMTS4 gene
expression. Increasing cytokine levels caused an increase in
ADAMTS4 expression however culture in the presence of EV
significantly decreased the expression of ADAMTS4 in all
conditions (Figure 5b). The effects of culturing chondrocytes
with 2 ng/ml of IL-1β in comparison to 1 ng/ml caused a large
drop in ACAN gene expression similar to levels seen at either
concentration of TNFα. The application of EV did not cause
any significant change to the chondrocyte ACANgene expres-
sion.
DISCUSSION
To the best of the authors’ knowledge, this study describes for
the first time, the isolation and characterisation of EV derived
from equine BM-MSC and demonstrates their ability to alter
gene expression of chondrocytes in the presence of IL-1β and
TNF-α.
The isolation of EV from equine tissue has been previously
described, with several studies detailing their isolation from
various equine tissues.25–29 Of these, four reports obtained
the EV from adipose-derived stem cells and the others were
isolated from amniotic stem cells.25–27,29,30 In these reports a
number of techniques were used to isolate EV including ultra-
centrifugation, size exclusion chromatography and precipita-
tion, all of which led to a yield of EV.25–30
In this study, we used a differential ultracentrifugation tech-
nique to isolate a population of EV from BM-MSC. This
technique allowed the isolation of a population of EV with
a mean size of 189 nm. In one study ultracentrifugation,
ultrafiltration and charge-based precipitation techniques were
used to isolate an EV population from horse adipose-derived
MSC,28 with ultrafiltration giving the highest and ultracen-
trifugation the lowest yield. This demonstrates that, as in
other species, multiple methods can be used to obtain EV.
In the study described here, we were able to isolate EV in a
reproducible fashion with the EV produced falling within a
narrow size range comparable to EV of other species.
The nature of the EV isolated from BM-MSC was demon-
strated using TEM and NTA analysis. The TEM is vital for
showing the structure of EV15 and, in this study, demon-
strated the presence of rounded vesicles of heterogeneous size
as previously reported.5,28,31,32 The NTA analysis was used
to measure the size distribution and the concentration of
the isolated EV in the samples studied. Whilst not without
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some technical limitations, NTA allows for the rapidmeasure-
ment of these parameters and is widely used in EV studies.15
The mean size of the bone marrow-derived MSC reported in
this study (186 nm) is similar to that reported for EV iso-
lated from adipose-derived MSC in the horse which was var-
iously reported as between 91 and 178 nm depending on the
method of isolation28 and in other species [mean size 112 nm
(murine)33 and 231 nm (human)].34
No protein characterisation was performed on the EV due
to a lack of cross-reactive antibodies available for this study.
This form of characterisation is recommended in the MISEV
2018 criteria for characterising EV; although the criteria are
mainly tailored towards EV of human origin.11 Future work
should investigate equine BM-MSC EV protein characterisa-
tion.
Having isolated EV from equine BM-MSC, we investi-
gated the interactions between the EV and a target cell in the
joint, the chondrocyte. Autologous chondrocytes from nor-
mal joints were grown in monolayer culture and incubated
with fluorescent labelled EV for one hour. Z-stack images,
acquired with confocal microscopy were used to identify EV
in the cellular environment, revealing that the EV were inter-
nalised into the cell. In several cells, multiple EV were present
and this led to a green cluster being observed. This uptake
of BM-MSC EV has previously been shown in osteoarthritic
human chondrocytes.35 To the best of the authors’ knowledge,
it has not been reported before in equine chondrocytes, nor-
mal or osteoarthritic. These results confirmed that the isolated
EV can be internalised by the potential target cell.
One of the key aims in the treatment of equine OA is
to inhibit further inflammation in the joint. In order to
demonstrate the anti-inflammatory actions of EV isolated
from BM-MSC, we investigated the effects of EV on the
gene expression of cartilage degrading factors (MMP-13 and
ADAMTS4) and pro-cartilage factor ACAN in the presence
of the inflammatory cytokines IL-1β or TNF-α at two dif-
ferent concentrations. Chondrocytes were co-cultured with
EVs such that the number of EVs added to the cells was
equivalent to those released from a 1:1 ratio of MSCs to chon-
drocytes as previously described in a human model35 and, as
such, the ‘dosage’ or EV was speculative in this experimental
model. Further work is required to elucidate the optimum
concentration of EV for maximum effect.
Culture in increasing concentrations of IL-1β or TNF-
α increased MMP-13 and ADAMTS4 expression in a dose
dependant manner as has been reported previously.36 The
BM-MSC-derived EV reduced the inflammatory effects of
IL-1β and TNFα in chondrocytes, significantly decreasing
the upregulation of gene expression of both MMP-13 and
ADAMTS4 at certain concentrations, as has been reported.
This anti-catabolic effect is similar to that reported for cor-
ticosteroids, a therapeutic agent used clinically to manage
equine OA.36,37
Whilst these results demonstrate that BM-MSC EV have
anti-inflammatory effects when chondrocytes are cultured in
the presence of IL-1β or TNF-α, no effect of culture in the
presence of EV on aggrecan gene expression was detected.
Despite high levels of IL-1β causing a large drop in the expres-
sion of ACAN gene expression, the application of EV was not
able to significantly increase ACAN gene expression. Altered
cytokine levels of TNF-α did not significantly affect ACAN
gene expression and nor was a significant effect noted when
EV were applied. This may be a preliminary indicator that EV
are not a tool for tissue regeneration, although this observa-
tion requires further investigation.
One limitation of the study is that the affectof EV on gene
expression of MMP-13, ADAMTS4 and ACAN on unstimu-
lated chondrocyteswas not included as a control; furthermore,
a control with only PBS and no EV could have been used. Fur-
ther studies merit inclusion of such control samples in order
to help verify the affects of EV on chondrocytes.
This study has demonstrated that equine BM-MSC pro-
duce EV can be isolated by differential sequential ultracen-
trifugation, that the EV can be internalised into chondrocytes
and have anti-catabolic properties when chondrocytes are cul-
tured in the presence of IL-1β or TNF-α.
Whilst MSC have been shown to be efficacious in the treat-
ment of joint disease in the horse,38,39 MSC therapy has inher-
ent drawbacks including provoking an immune response. In
addition, the practical challenges of removing equine bone
marrow and subsequent sterile cellular expansion prior to re-
injection makes MSC therapy prohibitively costly in many
cases. The results of this study show that BM-MSC EV should
be investigated further as a possible therapeutic intervention
for inflammatory joint disease in the horse.40
ACKNOWLEDGEMENTS
We thank Karin Newell for her continual help and support
throughout this project. We thank the Cambridge Advanced
Imaging Centre team for their help acquiring the electron
microscope images especially KarinMuller. This research was
supported by the Cambridge NIHR BRC Cell Phenotyping
Hub. We thank Matthew Rhodes of the Queen’s Veterinary
School Hospital, Anatomic Pathology team.
ETHICAL STATEMENT
All tissue was taken from cadaveric horses with the owners’
full consent.
AUTHOR CONTRIBUTIONS
William Edward Hotham and Charlotte Thompson equally
contributed to the data acquisition. Lin Szu-Ting is respon-
sible for osteogenic differentiation data acquisition. William
Edward Hotham led the manuscript production with
assistance from Charlotte Thompson, and Frances Mar-
garet Daphne Henson supervised the work and helped in
manuscript editing.
DATA AVAILAB IL ITY STATEMENT
The data that support the findings of this study are available





1. CaplanAI.Mesenchymal stem cells: time to change the name! StemCells
Transl Med. 2017;6:1445–51. http://doi.org/10.1002/sctm.17-0051
2. Smith RKW, Werling NJ, Dakin SG, Alam R, Goodship AE, Dudhia
J. Beneficial effects of autologous bone marrow-derived mesenchymal
stem cells in naturally occurring tendinopathy. PLoSOne. 2013;8:e75697.
3. Godwin EE, Young NJ, Dudhia J, Beamish IC, Smith RKW. Implan-
tation of bone marrow-derived mesenchymal stem cells demonstrates
improved outcome in horses with overstrain injury of the superficial dig-
ital flexor tendon. Equine Vet J. 2012;44:25–32.
 of  Veterinary Record Open
4. Broeckx SY, Seys B, Suls M, Vandenberghe A, Mariën T, Adriaensen E,
et al. Equine allogeneic chondrogenic induced mesenchymal stem sells
are an effective treatment for degenerative joint disease in horses. Stem
Cells Dev. 2019;28:410–22.
5. McIlwraith CW. Traumatic arthritis and Posttraumatic Osteoarthritis
in the Horse. In: McIlwraith CW, Frisbie DD, Kawcak EC, Weeren VR.
Joint disease in the horse, nd edition. St Louis, MO, USA: Elsevier, 2016,
pp 33–48.
6. Bertoni L, Branly T, Jacquet S, Desancé M, Desquilbet L, Rivory P,
et al. Intra-articular injection of 2 different dosages of autologous
and allogeneic bone marrow- and umbilical cord-derived mesenchy-
mal stem cells triggers a variable inflammatory response of the fet-
lock joint on 12 sound experimental horses. Stem Cells Int. 2019;2019:
9431894.
7. Drela K, Stanaszek L, Nowakowski A, Kuczynska Z, Lukomska B.
Experimental strategies of mesenchymal stem cell propagation: adverse
events and potential risk of functional changes. Stem Cells Int.
2019;2019:7012692.
8. Jifcovici A, SolanoMA, FitzpatrickN, Findji L, BlunnG, Sanghani-Kerai
A. Comparison of fat harvested from flank and falciform regions for
stem cell therapy in dogs. Vet Sci. 2021;8:19.
9. Lim P, Patel SA, Rameshwar P. Effective tissue repair and immunomod-
ulation by mesenchymal stem cells within a milieu of cytokines.
Gorodetsky R, Schäfer R, editors. Stem cell-based tissue repair. Cam-
bridge, UK, Royal Society of Chemistry; 2011. p. 346–365.
10. Baglio SR, Pegtel DM, Baldini N. Mesenchymal stem cell secreted vesi-
cles provide novel opportunities in (stem) cell-free therapy. Front Phys-
iol. 2012;3:359.
11. Théry C,Witwer KW, Aikawa E, Alcaraz MJ, Anderson JD, Andriantsi-
tohaina R, et al. Minimal information for studies of extracellular vesicles
2018 (MISEV2018): a position statement of the International Society for
Extracellular Vesicles and update of the MISEV2014 guidelines. J Extra-
cell Vesicles. 2018;7:1535750.
12. Da SilvaMeirelles L, Sand TT, Harman RJ, LennonDP, Caplan AI.MSC
frequency correlates with blood vessel density in equine adipose tissue.
Tissue Eng – Part A. 2009;15:221–9.
13. Lai RC, Arslan F, Lee MM, Sze NSK, Choo A, Chen TS, et al. Exosome
secreted by MSC reduces myocardial ischemia/reperfusion injury. Stem
Cell Res. 2010;4:214–22.
14. Rougerie P,Miskolci V, CoxD.Generation ofmembrane structures dur-
ing phagocytosis and chemotaxis of macrophages: role and regulation of
the actin cytoskeleton. Immunol. Rev. 2013;256:222–39.
15. Hartjes TA, Mytnyk S, Jenster GW, van Steijn V, van Royen ME. Extra-
cellular vesicle quantification and characterization: Common methods
and emerging approaches. Bioengineering. 2019;6:7.
16. Lee Y, Andaloussi SEL, WoodMJA. Exosomes and microvesicles: extra-
cellular vesicles for genetic information transfer and gene therapy. Hum
Mol Genet. 2012;21:125–34.
17. Ge R, Tan E, Sharghi-Namini S, Asada HH. Exosomes in cancer
microenvironment and beyond: have we overlooked these extracellular
messengers? Cancer Microenviron. 2012;5:323–32.
18. Mulcahy LA, Pink RC, Carter DRF. Routes andmechanisms of extracel-
lular vesicle uptake. J Extracell Vesicles. 2014;3:24641.
19. György B, Szabó TG, Pásztói M, Pál Z, Misják P, Aradi B, László V, et al.
Membrane vesicles, current state-of-the-art: emerging role of extracel-
lular vesicles. Cell Mol Life Sci. 2011;68:2667–88.
20. Uder C, Brückner S, Winkler S, Tautenhahn HM, Christ B. Mammalian
MSC from selected species: Features and applications. Cytom Part A.
2018;93:32–49.
21. Cosenza S, Ruiz M, Toupet K, Jorgensen C, Noël D. Mesenchy-
mal stem cells derived exosomes and microparticles protect carti-
lage and bone from degradation in osteoarthritis. Sci Rep. 2017;7:
16214.
22. Carpenter RS, Goodrich LR, Frisbie DD, Kisiday JD, Carbone B, McIl-
wraith CW, et al. Osteoblastic differentiation of human and equine adult
bone marrow-derived mesenchymal stem cells when BMP-2 or BMP-7
homodimer genetic modification is compared to BMP-2/7 heterodimer
genetic modification in the presence and absence of dexamethasone. J
Orthop Res. 2010;28:1330–7.
23. Lombana KG, Goodrich LR, Phillips JN, Kisiday JD, Ruple-Czerniak A,
WayneMcllwraith C. An investigation of equine mesenchymal stem cell
characteristics from different harvest sites: More similar than not. Front
Vet Sci. 2015;2:7.
24. Subedi P, Schneider M, Philipp J, Azimzadeh O, Metzger F, Moertl S,
et al. Comparison of methods to isolate proteins from extracellular vesi-
cles for mass spectrometry-based proteomic analyses. Anal Biochem.
2019;584:113390.
25. Lange-Consiglio A, Perrini C, Deregibus MC, Camussi G, Tasquier
R, Pascucci L, et al. Equine Amniotic Microvesicles and Their Anti-
Inflammatory Potential in a Tenocyte Model In Vitro. Stem Cells Dev.
2016;15:610–21.
26. Pascucci L, Dall’Aglio C Bazzucchi C. Horse adipose-derivedmesenchy-
mal stromal cells constitutively produce membrane vesicles: a morpho-
logical study. Histol Histopathol. 2015;30:549–57.
27. Pascucci L, Alessandri G, Dall’Aglio C Mercati F. Membrane vesicles
mediate pro-angiogenic activity of equine adipose-derived mesenchy-
mal stromal cells. Vet J. 2014;202:361–6.
28. Klymiuk MC, Balz N, Elashry MI, Heimann M, Wenisch S Arnhold S.
Exosomes isolation and identification from equine mesenchymal stem
cells. BMC Vet Res. 2019;15:42.
29. Capomaccio S, Cappelli K, Bazzucchi C, Coletti M, Gialletti R,Moriconi
F, et al. Equine adipose-derivedmesenchymal stromal cells release extra-
cellular vesicles enclosing different subsets of small RNAs. StemCells Int.
2019;2019:4957806.
30. Perrini C, Strillacci MG, Bagnato A, Esposti P, Marini MG, Corradetti
B, et al. Microvesicles secreted from equine amniotic-derived cells and
their potential role in reducing inflammation in endometrial cells in an
in-vitro model. Stem Cell Res Ther. 2016;7:169.
31. Dabrowska S, Fattore ADel, Karnas E, Frontczak-Baniewicz M,
Kozlowska H, Muraca M, et al. Imaging of extracellular vesicles derived
from human bone marrow mesenchymal stem cells using fluorescent
and magnetic labels. Int J Nanomed. 2018;13:1653–64.
32. Rajendran RL, Gangadaran P, Bak SS, Oh JM, Kalimuthu S, Lee HW,
et al. Extracellular vesicles derived from MSCs activates dermal papilla
cell in vitro and promotes hair follicle conversion from telogen to anagen
in mice. Sci. Rep. 2017;7:15560.
33. Haga H, Yan IK, Takahashi K, Matsuda A, Patel T. Extracellular vesicles
from bone marrow-derived mesenchymal stem cells improve survival
from lethal hepatic failure in mice. Stem Cells Transl Med. 2017;6:1262–
72.
34. Wen S, Dooner M, Papa E, Tatto MDel, Pereira M, Borgovan T, et al.
Biodistribution of mesenchymal stem cell-derived extracellular vesi-
cles in a radiation injury bone marrow murine model. Int J Mol Sci.
2019;20:5468.
35. Vonk LA, van Dooremalen SFJ, Liv N, Klumperman J, Coffer PJ,
Saris DBF, et al. Mesenchymal stromal/stem cell-derived extracellular
vesicles promote human cartilage regeneration in vitro. Theranostics.
2018;8:906–20.
36. Richardson DW, Dodge GR. Effects of interleukin-1β and tumor necro-
sis factor-α on expression of matrix-related genes by cultured equine
articular chondrocytes. Am J Vet Res. 2000;61:624–30.
37. Caron JP, Gandy JC, Schmidt M, Hauptman JG, Sordillo LM. Influ-
ence of corticosteroids on interleukin-1β-stimulated equine chondrocyte
gene expression. Vet Surg. 2013;42:231–7.
38. Barrachina L, Remacha AR, Romero A, Vitoria A, Albareda J, Prades
M, et al. Assessment of effectiveness and safety of repeat administra-
tion of proinflammatory primed allogeneic mesenchymal stem cells in
an equine model of chemically induced osteoarthritis. BMC Vet Res.
2018;14:241.
39. Broeckx S, Suls M, Beerts C, Vandenberghe A, Seys B, Wuertz-Kozak K,
et al. Allogenic mesenchymal stem cells as a treatment for equine degen-
erative joint disease: a pilot study. Curr Stem Cell Res Ther. 2014;9:497–
503.
40. Boere J, Malda J, van de Lest CHA, Weeren PR van Wauben MHM.
Extracellular vesicles in joint disease and therapy. Front Immunol.
2018;9:2575.
How to cite this article: HothamWE, Thompson C,
Szu-Ting L, Henson FMD. The anti-inflammatory
effects of equine bone marrow stem cell-derived
extracellular vesicles on autologous chondrocytes.
Vet Rec Open. 2021;:e22.
https://doi.org/10.1002/vro2.22
